Jeroan Allison to Antiretroviral Therapy, Highly Active
This is a "connection" page, showing publications Jeroan Allison has written about Antiretroviral Therapy, Highly Active.
Connection Strength
0.223
-
Nevin CR, Ye J, Aban I, Mugavero MJ, Jackson D, Lin HY, Allison J, Raper JL, Saag MS, Willig JH. The role of toxicity-related regimen changes in the development of antiretroviral resistance. AIDS Res Hum Retroviruses. 2011 Sep; 27(9):957-63.
Score: 0.092
-
Robison LS, Westfall AO, Mugavero MJ, Kempf MC, Cole SR, Allison JJ, Willig JH, Raper JL, Wilcox CM, Saag MS. Short-term discontinuation of HAART regimens more common in vulnerable patient populations. AIDS Res Hum Retroviruses. 2008 Nov; 24(11):1347-55.
Score: 0.078
-
Ulett KB, Willig JH, Lin HY, Routman JS, Abroms S, Allison J, Chatham A, Raper JL, Saag MS, Mugavero MJ. The therapeutic implications of timely linkage and early retention in HIV care. AIDS Patient Care STDS. 2009 Jan; 23(1):41-9.
Score: 0.020
-
Willig JH, Abroms S, Westfall AO, Routman J, Adusumilli S, Varshney M, Allison J, Chatham A, Raper JL, Kaslow RA, Saag MS, Mugavero MJ. Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy. AIDS. 2008 Oct 01; 22(15):1951-60.
Score: 0.019
-
Bedimo R, Chen RY, Accortt NA, Raper JL, Linn C, Allison JJ, Dubay J, Saag MS, Hoesley CJ. Trends in AIDS-defining and non-AIDS-defining malignancies among HIV-infected patients: 1989-2002. Clin Infect Dis. 2004 Nov 01; 39(9):1380-4.
Score: 0.015